LIFE TECHNOLOGIES CORP 
By
New GeneArt® Algae Protein Expression Kits From Life Technologies
New kits enable researchers to freeze Chlamydomonas reinhardtii, boost protein production and cloning efficiencies
CARLSBAD, Calif., December 10, 2013 - Life Technologies Corporation today announced that the company has expanded their GeneArt® Algae Engineering portfolio. The new kits contain features requested by algae biologists and are designed to make work with algae simpler and faster. The GeneArt® kits represent the first commercially available genetic modification and expression systems for photosynthetic microalgae Chlamydomonas reinhardtii and Synechococcus elongatus.
The GeneArt® Chlamydomonas Protein Expression Kits and GeneArt® Synechoccus Protein Expression Kits contain high-expression vectors capable of driving production of genes of interest to as much as 10 percent of total cellular protein. The kits also contain new proprietary transformation reagents that can boost introduction of DNA into cells by as much as a thousand-fold over what is typically achieved with current techniques.
"By combining high levels of both DNA transformation and protein expression, the new GeneArt® kits allow investigators to move beyond basic research into more of a production mode and applied science," said Nathan Wood, general manager and vice president of synthetic biology for Life Technologies. "These were features specifically requested by users of our first generation kits, and we believe these capabilities will help algae biologists advance their field to level of ease that typifies work with yeast and E. coli."
The new GeneArt® kits also contain reagents and a protocol enabling researchers to freeze and store Chlamydomonas strains at -80°C. Algal researchers have traditionally relied on passaging strains indefinitely, which makes the cultures subject to genetic drift, and shipping live cultures on agar slants, which frequently become contaminated.
"A protocol for freezing their own clones is one of the most frequent requests we receive from customers," said Wood. "It will facilitate standardization of these important model organisms and allow rapid exchange among investigators that will facilitate progress in the field."
Algae serve as model organisms for the study of photosynthesis, circadian rhythms and nutrient-regulated gene activity, and are being investigated for bioproduction of biofuels, nutraceuticals and specialty chemicals.
For research use only. Not for use in diagnostic procedures.
About Life Technologies
Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com
CARLSBAD, Calif., December 10, 2013 - Life Technologies Corporation today announced that the company has expanded their GeneArt® Algae Engineering portfolio. The new kits contain features requested by algae biologists and are designed to make work with algae simpler and faster. The GeneArt® kits represent the first commercially available genetic modification and expression systems for photosynthetic microalgae Chlamydomonas reinhardtii and Synechococcus elongatus.
The GeneArt® Chlamydomonas Protein Expression Kits and GeneArt® Synechoccus Protein Expression Kits contain high-expression vectors capable of driving production of genes of interest to as much as 10 percent of total cellular protein. The kits also contain new proprietary transformation reagents that can boost introduction of DNA into cells by as much as a thousand-fold over what is typically achieved with current techniques.
"By combining high levels of both DNA transformation and protein expression, the new GeneArt® kits allow investigators to move beyond basic research into more of a production mode and applied science," said Nathan Wood, general manager and vice president of synthetic biology for Life Technologies. "These were features specifically requested by users of our first generation kits, and we believe these capabilities will help algae biologists advance their field to level of ease that typifies work with yeast and E. coli."
The new GeneArt® kits also contain reagents and a protocol enabling researchers to freeze and store Chlamydomonas strains at -80°C. Algal researchers have traditionally relied on passaging strains indefinitely, which makes the cultures subject to genetic drift, and shipping live cultures on agar slants, which frequently become contaminated.
"A protocol for freezing their own clones is one of the most frequent requests we receive from customers," said Wood. "It will facilitate standardization of these important model organisms and allow rapid exchange among investigators that will facilitate progress in the field."
Algae serve as model organisms for the study of photosynthesis, circadian rhythms and nutrient-regulated gene activity, and are being investigated for bioproduction of biofuels, nutraceuticals and specialty chemicals.
For research use only. Not for use in diagnostic procedures.
About Life Technologies
Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact:
Suzanne Clancy
760-602-4545
858-205-4235 (mobile)
suzanne.clancy@lifetech.com
|
distributed by
|
